ANI Deferred Long Term Liab from 2010 to 2024

ANIP Stock  USD 60.36  1.30  2.11%   
ANI Pharmaceuticals Deferred Long Term Liabilities yearly trend continues to be relatively stable with very little volatility. Deferred Long Term Liabilities is likely to drop to about 458.1 K. Deferred Long Term Liabilities is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. View All Fundamentals
 
Deferred Long Term Liabilities  
First Reported
2011-06-30
Previous Quarter
600 K
Current Value
500 K
Quarterly Volatility
437.1 K
 
Yuan Drop
 
Covid
Check ANI Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ANI main balance sheet or income statement drivers, such as Depreciation And Amortization of 62.8 M, Interest Expense of 28.9 M or Selling General Administrative of 157.9 M, as well as many exotic indicators such as Price To Sales Ratio of 1.94, Dividend Yield of 0.0012 or PTB Ratio of 2.18. ANI financial statements analysis is a perfect complement when working with ANI Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement ANI Pharmaceuticals' financial leverage analysis and stock options assessment as well as various ANI Pharmaceuticals Technical models . Check out the analysis of ANI Pharmaceuticals Correlation against competitors.
To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.

Latest ANI Pharmaceuticals' Deferred Long Term Liab Growth Pattern

Below is the plot of the Deferred Long Term Liab of ANI Pharmaceuticals over the last few years. It is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. ANI Pharmaceuticals' Deferred Long Term Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ANI Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Deferred Long Term Liab10 Years Trend
Slightly volatile
   Deferred Long Term Liab   
       Timeline  

ANI Deferred Long Term Liab Regression Statistics

Arithmetic Mean409,671
Geometric Mean0.00
Coefficient Of Variation111.11
Mean Deviation382,359
Median458,059
Standard Deviation455,187
Sample Variance207.2B
Range1.5M
R-Value0.64
Mean Square Error133B
R-Squared0.40
Significance0.01
Slope64,694
Total Sum of Squares2.9T

ANI Deferred Long Term Liab History

2024458.1 K
2023690 K
2022600 K
2020500 K
2019800 K
20181.5 M
2017829 K

About ANI Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include ANI Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. ANI Pharmaceuticals investors use historical funamental indicators, such as ANI Pharmaceuticals's Deferred Long Term Liab, to determine how well the company is positioned to perform in the future. Although ANI Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in ANI Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on ANI Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on ANI Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in ANI Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Deferred Long Term Liabilities690 K458.1 K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether ANI Pharmaceuticals is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if ANI Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Ani Pharmaceuticals Stock. Highlighted below are key reports to facilitate an investment decision about Ani Pharmaceuticals Stock:
Check out the analysis of ANI Pharmaceuticals Correlation against competitors.
To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.
You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Complementary Tools for ANI Stock analysis

When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Global Correlations
Find global opportunities by holding instruments from different markets
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Valuation
Check real value of public entities based on technical and fundamental data
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Is ANI Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ANI Pharmaceuticals. If investors know ANI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ANI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
13.824
Earnings Share
1.61
Revenue Per Share
27.705
Quarterly Revenue Growth
0.287
Return On Assets
0.0391
The market value of ANI Pharmaceuticals is measured differently than its book value, which is the value of ANI that is recorded on the company's balance sheet. Investors also form their own opinion of ANI Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ANI Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ANI Pharmaceuticals' market value can be influenced by many factors that don't directly affect ANI Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ANI Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ANI Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ANI Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.